GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cresco Labs Inc (OTCPK:CRLWF) » Definitions » EBIT

CRLWF (Cresco Labs) EBIT : $58.92 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cresco Labs EBIT?

Cresco Labs's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $27.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $58.92 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cresco Labs's annualized ROC % for the quarter that ended in Sep. 2024 was -6.96%. Cresco Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 21.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


Cresco Labs EBIT Historical Data

The historical data trend for Cresco Labs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cresco Labs EBIT Chart

Cresco Labs Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.38 -31.53 -204.58 -68.39 -83.66

Cresco Labs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -104.56 27.43 30.77 -26.38 27.11

Competitive Comparison of Cresco Labs's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cresco Labs's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cresco Labs's EV-to-EBIT falls into.



Cresco Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $58.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cresco Labs  (OTCPK:CRLWF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cresco Labs's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=114.652 * ( 1 - 167.96% )/( (1131.799 + 1107.154)/ 2 )
=-77.9174992/1119.4765
=-6.96 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1358.046 - 113.951 - ( 112.296 - max(0, 136.876 - 273.368+112.296))
=1131.799

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1382.932 - 122.483 - ( 153.295 - max(0, 158.569 - 311.918+153.295))
=1107.154

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cresco Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=108.436/( ( (473.236 + max(47.121, 0)) + (465.141 + max(32.946, 0)) )/ 2 )
=108.436/( ( 520.357 + 498.087 )/ 2 )
=108.436/509.222
=21.29 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(54.215 + 95.151 + 11.706) - (113.951 + 0 + 0)
=47.121

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(54.562 + 92.238 + 11.291) - (122.483 + 2.662 + -2.8421709430404E-14)
=32.946

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cresco Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=58.921/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cresco Labs EBIT Related Terms

Thank you for viewing the detailed overview of Cresco Labs's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cresco Labs Business Description

Traded in Other Exchanges
Address
400 West Erie Street, Suite 110, Chicago, IL, USA, 60654
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, Cresco Labs' national dispensary brand and others. The Company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis.